Evidence mapPaperPMID 38726719Full record

Trial reportEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2024

Quantitative flow ratio versus fractional flow reserve for Heart Team decision-making in multivessel disease: the randomised, multicentre DECISION QFR trial.

Taku Asano, Toru Tanigaki, Masahiro Hoshino, Motoki Yasunaga, Hideaki Nonaka, Hiroki Emori, Yuki Katagiri, Yosuke Miyazaki, Yohei Sotomi, Norihiro Kogame and 25 more

Abstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Coronary revascularisation deferral based on quantitative flow ratio or fractional flow reserve: a post hoc analysis of the FAVOR III Europe trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025
    Trial
  2. Age-Specific Cardiovascular and Platelet Dynamics in Kawasaki Disease.International journal of general medicine · 2025
    Article
  3. Leveraging QFR and SYNTAX score II 2020 to guide PCI versus CABG decisions in multivessel CAD - broadening QFR's utility.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Taku AsanoDepartment of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Toru TanigakiDepartment of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.
Masahiro HoshinoDivision of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan.
Motoki YasunagaCardiovascular Division, Osaka Police Hospital, Osaka, Japan.
Hideaki NonakaDivision of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.
Hiroki EmoriDepartment of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.
Yuki KatagiriDepartment of Cardiovascular Medicine, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan.
Yosuke MiyazakiDivision of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Yohei SotomiDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
Norihiro KogameDivision of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.
Shoichi KuramitsuSapporo Cardiovascular Clinic, Sapporo Heart Center, Sapporo, Japan.
Akira SaitoDepartment of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Kotaro MiyataDepartment of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Yoshimitsu TakaokaDepartment of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Takayoshi KanieDepartment of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Manabu YamasakiDepartment of Cardiovascular Surgery, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Kunihiko YoshinoDepartment of Cardiovascular Surgery, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Naoki WakabayashiDepartment of Radiology, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Kouki OuchiDepartment of Radiology, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Hiroyuki KodamaDepartment of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Yumi ShiinaDepartment of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Rihito TamakiDepartment of Cardiovascular Surgery, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Yosuke NishihataDepartment of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Keita MasudaDepartment of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Takahiro SuzukiDepartment of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Johan H C ReiberDepartment of Radiology, Leiden University Medical Center, Leiden, the Netherlands.
Takayuki OkamuraDivision of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Yoshiharu HiguchiCardiovascular Division, Osaka Police Hospital, Osaka, Japan.
Tsunekazu KakutaDivision of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan.
Hiroyasu MisumiDepartment of Cardiovascular Surgery, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Kohei AbeDepartment of Cardiovascular Surgery, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Nobuyuki KomiyamaDepartment of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Kengo TanabeDivision of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.
Hitoshi MatsuoDepartment of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.
On Behalf Of The Decision Qfr Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVessel-level physiological data derived from pressure wire measurements are one of the important determinant factors in the optimal revascularisation strategy for patients with multivessel disease (MVD). However, these may result in complications and a prolonged procedure time.

aimsThe feasibility of using the quantitative flow ratio (QFR), an angiography-derived fractional flow reserve (FFR), in Heart Team discussions to determine the optimal revascularisation strategy for patients with MVD was investigated.

methodsTwo Heart Teams were randomly assigned either QFR- or FFR-based data of the included patients. They then discussed the optimal revascularisation mode (percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]) for each patient and made treatment recommendations. The primary endpoint of the trial was the level of agreement between the treatment recommendations of both teams as assessed using Cohen's kappa.

resultsThe trial included 248 patients with MVD from 10 study sites. Cohen's kappa in the recommended revascularisation modes between the QFR and FFR approaches was 0.73 [95% confidence interval {CI} : 0.62-0.83]. As for the revascularisation planning, agreements in the target vessels for PCI and CABG were substantial for both revascularisation modes (Cohen's kappa=0.72 [95% CI: 0.66-0.78] and 0.72 [95% CI: 0.66-0.78], respectively). The team assigned to the QFR approach provided consistent recommended revascularisation modes even after being made aware of the FFR data (Cohen's kappa=0.95 [95% CI:0.90-1.00]).

conclusionsQFR provided feasible physiological data in Heart Team discussions to determine the optimal revascularisation strategy for MVD. The QFR and FFR approaches agreed substantially in terms of treatment recommendations.

Indexed as

Coronary AngiographyCoronary Artery DiseaseFractional Flow Reserve, MyocardialPercutaneous Coronary InterventionAgedCardiac CatheterizationClinical Decision-MakingCoronary Artery BypassFemaleHumansMaleMiddle AgedPatient Care Team

Identifiers

PMID38726719
PMCPMC11067723

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.